Translatum Medicus - Crunchbase Company Profile & Funding

Q: Where is Translatum Medicus's headquarters?

Translatum Medicus is located in Toronto, Ontario, Canada.

Overview

Translatum Medicus

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Translatum Medicus

CB Rank

747193

Translatum Medicus is a biotechnology company that fixates on preclinical drug development to treat irreversible blindness.

Founded

obfuscation

Private

Toronto, Ontario, Canada

11-50

www.translatummedicus.com

Biotechnology

Medical

Pharmaceutical

Key People

Shelley Boyd: Founding President, CSO & CEO
Paul G. Howes: EVP, Strategy & Business Development

Details

Also Known As

TMI

Operating Status

Active

Company Type

For Profit

Founders

Shelley Boyd

Phone Number

+1 6472435236

Contact Email

info@translatummedicus.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

TMi-018

A transcriptional modulator targeting macrophage activity to reduce transcription of DNA to RNA, aimed at treating Dry Age-Related Macular Degeneration (AMD) and other ophthalmic conditions.

Precision Drug Development

A method focusing on matching the right patient with the right study and treatment, particularly for Dry AMD, using image-based biomarkers and clinical trial endpoints.